Correspondence on reply to “Quantitative fragility of reported association between aspirin use and hepatocellular carcinoma risk in MASLD”
Clinical and Molecular Hepatology · 06.11.2026
DOI: 10.3350/cmh.2026.0511 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical and Molecular Hepatology, online erschienen am 06.11.2026. Verfasst von Shi-Jie Zhang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Children's Medical Center, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China.
Abstract (Originalsprache)
This correspondence is in response to [Reply to "Quantitative fragility of reported association between aspirin use and hepatocellular carcinoma risk in MASLD"]
Autor:innen und Institutionen
- Children's Medical Center, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China.
- The Affiliated Hospital of Guizhou Medical University, Guizhou Medical University, Guizhou, China. gaoguiying@gmc.edu.cn.
Zitieren
APA
Zhang, S. J., & Gao, G. (2026). Correspondence on reply to “Quantitative fragility of reported association between aspirin use and hepatocellular carcinoma risk in MASLD”. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2026.0511
Vancouver
Zhang SJ, Gao G. Correspondence on reply to “Quantitative fragility of reported association between aspirin use and hepatocellular carcinoma risk in MASLD”. Clinical and Molecular Hepatology. 2026. doi:10.3350/cmh.2026.0511
BibTeX
@article{Zhang2026,
author = {Zhang, Shi-Jie and Gao, Guiying},
title = {Correspondence on reply to “Quantitative fragility of reported association between aspirin use and hepatocellular carcinoma risk in MASLD”},
journal = {Clinical and Molecular Hepatology},
year = {2026},
doi = {10.3350/cmh.2026.0511}
}
EUVIMED